CRO

Chinese regulators crack down on counterfeiters; BASi reports 14% revenue drop in Q3;

> Chinese regulators are sick of counterfeit drugs and devices getting into the company's market, so the government is publishing a blacklist of manufacturers and suppliers who have run afoul of Chinese law. Item

> BASi ($BASi) saw its revenue drop 14% to $7.2 million in the third quarter, but the company is optimistic about its future growth. News

> WuXi PharmaTech's Suzhou facility received GLP certification from China's State Food and Drug Administration, allowing the company to perform non-clinical lab studies there. Article

> IMS Health has purchased TTC, an outfit that specializes in calculating cost and negotiating prices for clinical trials. The company didn't disclose an acquisition price. More

> The FDA has updated its guidance on suicide risk in clinical trials, responding to increasing reports of certain populations taking antidepressants and antiepileptics. Story

> DaVita is opening a Colorado Phase I facility to focus on kidney research, targeting drugmakers seeking renal trials. Report